We are fortunate to advise world-class, industry-leading companies, helping them tackle novel, complex issues and push the boundaries of technological progress. Our ability and confidence to go to trial is our core strength; our deep bench of experienced trial lawyers represents companies in their most significant matters, helping them protect their intellectual property and launch products. Our lawyers pair extensive experience in the courtroom and the boardroom with a thorough understanding of science and technology.
Outside Counsel: 'MedImmune v. Genentech': Unanswered Questions
February 1, 2007 Full PDF
Litigation partner Catherine Nyarady published an article, "'MedImmune v. Genentech': Unanswered Questions," in the February 1 New York Law Journal. The article discusses the Supreme Court's ruling, which held that a patent licensee has jurisdiction to seek a declaratory judgement of noninfringement, patent invalidity or unenforceability against the licensor-patentee, even if the licensee continues to pay royalties under the license agreement. This decision reversed the previous ruling by the U.S. Court of Appeals for the Federal Circuit. The article also reflects on some important issues the Supreme Court left unanswered in the case. Associate Benjamin Warlick assisted with the preparation of this article.